BusinessTonix Pharmaceuticals’ PTSD Phase 3-Ready Drug Candidate, TNX-102 SL, Granted Breakthrough Therapy Designation by the FDABy Nasdaq OMXDec 19, 2016, 12:00 PM UTC
BusinessCatalyst Pharmaceuticals Announces First Patient Enrolled in Second Phase 3 Trial of Firdapse in Lambert-Eaton myasthenic syndrome (LEMS)By Nasdaq OMXDec 15, 2016, 1:03 PM UTC
BusinessPROTAGEN Launches NavigAID Assay to Support Clinical Drug Development for Autoimmune DiseasesBy Nasdaq OMXDec 13, 2016, 3:52 PM UTC
BusinessAXIM® Biotech Expands Advisory Board With Psychiatry Specialist – Dr. Ilya ReznikBy Nasdaq OMXDec 13, 2016, 2:00 PM UTC
BusinessArbutus Provides Additional Data from the ARB-1467 Phase II Clinical Trial in HBV PatientsBy Nasdaq OMXDec 12, 2016, 9:00 PM UTC
BusinessCatalyst Pharmaceuticals Provides Update on its Clinical Trial for Patients with Congenital Myasthenic SyndromesBy Nasdaq OMXDec 8, 2016, 1:03 PM UTC
BusinessKaryopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual MeetingBy Nasdaq OMXDec 5, 2016, 10:45 PM UTC
BusinessNanoString Technologies Highlights Presentation of Multiple Prosigna/PAM50 and Immuno-Oncology Studies at the 39th Annual CTRC-AACR San Antonio Breast Cancer SymposiumBy Nasdaq OMXDec 5, 2016, 10:23 PM UTC
